Form 4: Madrigal Pharmaceuticals CEO William Sibold Receives Stock and Option Grants
SEC Form 4
William Sibold, CEO of Madrigal Pharmaceuticals, was granted restricted stock units and stock options on March 5, 2025, according to a Form 4 filing.
Summary
- William John Sibold, the President and CEO of Madrigal Pharmaceuticals, received a grant of 13,066 restricted stock units on March 5, 2025.
- These restricted stock units vest in four equal installments on March 5 of 2026, 2027, 2028, and 2029, contingent upon continued service with the company.
- Sibold also received an option to buy 22,009 shares of common stock at a price of $347.28 on March 5, 2025.
- The options vest 25% on March 5, 2026, and then 6.25% every three months thereafter, also contingent upon continued service.
- Following these transactions, Sibold directly owns 117,369 shares of common stock and 22,009 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The grant of stock options and restricted stock units is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no explicitly negative aspects presented in the filing.
Positives
- The grant of restricted stock units and stock options aligns the CEO's interests with those of the shareholders, incentivizing him to drive long-term value creation.
- The vesting schedules for both the restricted stock units and stock options encourage continued service and commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.
Industry Context
Executive compensation packages, including stock options and restricted stock units, are common in the pharmaceutical industry to incentivize leadership and align their interests with shareholders, particularly in companies focused on long-term drug development and regulatory approvals.
Comparison to Industry Standards
- Stock option and RSU grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like Gilead Sciences, Amgen, and Biogen also utilize similar equity-based compensation to incentivize their executives.
- The vesting schedules described are typical, with vesting occurring over a multi-year period contingent on continued service.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of the grant of restricted stock units and stock options. |
| 03/05/2026 | First vesting date for 25% of the restricted stock units and stock options. |
| 03/05/2027 | Second vesting date for 25% of the restricted stock units. |
| 03/05/2028 | Third vesting date for 25% of the restricted stock units. |
| 03/05/2029 | Final vesting date for 25% of the restricted stock units. |
| 03/05/2035 | Expiration date of the stock options. |
| 03/07/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.